evaluates progression to liver decompensation events in patients with compensated NASH cirrhosis treated with Rezdiffra versus placebo. A positive outcome is expected to support the full ...

NASH is a form of non-alcoholic fatty ... including progression to cirrhosis and hepatic decompensation events, as well as all-cause mortality. PathAI's artificial intelligence tool for diagnosing ...

MAESTRO NASH Outcomes is a large Phase 3 double blind placebo-controlled trial evaluating progression to liver decompensation events in 845 patients with compensated MASH cirrhosis. We expect to ...

MAESTRO-NASH outcomes is a large Phase 3 double blind placebo controlled trial evaluating progression to liver decompensation events in 845 patients with compensated MASH cirrhosis. We expect to ...

a second phase III outcomes study (MAESTRO-NASH OUTCOMES) is underway, evaluating the progression to liver decompensation events in patients with compensated MASH cirrhosis treated with Rezdiffra ...

3 Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 4 Division of Gastroenterology and Hepatology, Department of Medicine, National University Health ...

We present the case of a woman in her 60s who was admitted due to decompensated ... cirrhosis, primary cholangitis and autoimmune hepatitis, were also excluded following a negative autoimmune work-up.

Resmetirom offers a targeted approach to metabolic dysfunction–associated steatohepatitis (MASH) for use alongside lifestyle ...

Non-Alcoholic Steatohepatitis (NASH): Fatty liver with inflammation and damage, which may progress to cirrhosis and liver cancer. Worldwide, 1 billion people are affected. In India, 18-20% of the ...

A European Medicines Agency committee, on Thursday, accepted the use of an artificial intelligence (AI) tool called AIM-NASH ...